R Cebolla Rosell
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.05%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 302
- Lung Cancer Diagnosis and Treatment 61
- Oncology 263
- Lung Cancer Research Studies 98
- Cancer Immunotherapy and Biomarkers 58
- Colorectal Cancer Treatments and Studies 37
- Co-authors
- Niki Karachaliou (149 shared papers)Tony S.K. Mok (20 shared papers)Giorgio V. Scagliotti (12 shared papers)Miquel Tarón (54 shared papers)Miguel Ángel Molina‐Vila (74 shared papers)Santiago Viteri (66 shared papers)Frances Alice Shepherd (15 shared papers)Vincent A. Miller (3 shared papers)
- Journals
- Annals of Oncology (46 papers)Journal of Thoracic Oncology (42 papers)Lung Cancer (34 papers)Translational Lung Cancer Research (26 papers)Journal of Clinical Oncology (22 papers)
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
R Cebolla Rosell
574 papers receiving 37.3k citations
R Cebolla Rosell's Hit Papers
Peers
Comparison fields: 5 of 170
- Pulmonary and Respiratory Medicine 19.5k
- Oncology 15.6k
- Cancer Research 6.6k
- Molecular Biology 11.4k
- Pathology and Forensic Medicine 2.1k
Countries citing papers authored by R Cebolla Rosell
This map shows the geographic impact of R Cebolla Rosell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Cebolla Rosell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Cebolla Rosell more than expected).
Fields of papers citing papers by R Cebolla Rosell
This network shows the impact of papers produced by R Cebolla Rosell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Cebolla Rosell. The network helps show where R Cebolla Rosell may publish in the future.
Co-authors
The 25 scholars most cited alongside R Cebolla Rosell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 591 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group Hit paper breakdown → | 2008 | 2058 |
| 2 | Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 1923 |
| 3 | Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 Hit paper breakdown → | 2004 | 1466 |
| 4 | Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Hit paper breakdown → | 2004 | 1453 |
| 5 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Hit paper breakdown → | 2006 | 1270 |
| 6 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry Hit paper breakdown → | 2019 | 1055 |
| 7 | Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Hit paper breakdown → | 2012 | 1053 |
| 8 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 995 |
| 9 | Non-small-cell lung cancer Hit paper breakdown → | 2015 | 839 |
| 10 | Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Hit paper breakdown → | 1999 | 805 |
| 11 | Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study Hit paper breakdown → | 2020 | 491 |
| 12 | The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies Hit paper breakdown → | 2015 | 462 |
| 13 | 1999 | 408 | |
| 14 | Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Hit paper breakdown → | 2020 | 383 |
| 15 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations Hit paper breakdown → | 2018 | 376 |
| 16 | 2011 | 345 | |
| 17 | 1996 | 307 | |
| 18 | Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial Hit paper breakdown → | 2016 | 305 |
| 19 | 2002 | 298 | |
| 20 | Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 298 |
About R Cebolla Rosell
R Cebolla Rosell is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 591 papers that have together received 38.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (302 papers), Lung Cancer Research Studies (98 papers), Cancer Genomics and Diagnostics (76 papers), Lung Cancer Diagnosis and Treatment (61 papers), Cancer Immunotherapy and Biomarkers (58 papers), Cancer therapeutics and mechanisms (47 papers), Colorectal Cancer Treatments and Studies (37 papers) and DNA Repair Mechanisms (30 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (19.5k citations), Oncology (15.6k citations), Cancer Research (6.6k citations), Molecular Biology (11.4k citations) and Pathology and Forensic Medicine (2.1k citations). R Cebolla Rosell has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Niki Karachaliou, Tony S.K. Mok, Giorgio V. Scagliotti, Miquel Tarón, Miguel Ángel Molina‐Vila, Santiago Viteri, Frances Alice Shepherd, Vincent A. Miller, Joan H. Schiller and Christian Manegold. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Translational Lung Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.